Hydrocodone

# Research Output: Hydrocodone

---

## Chemical Identity

### Verified Data (PubChem CID 5284569)

| Property | Value | Source |
|---|---|---|
| PubChem CID | 5284569 | PubChem API [database lookup] |
| CAS Number | 125-29-1 | Web-retrieved [Ref 18] |
| Molecular Formula | C18H21NO3 | PubChem API [Ref — database lookup] |
| Molecular Weight | 299.4 g/mol | PubChem API |
| IUPAC Name | (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one | PubChem API |
| InChIKey (stereospecific) | LLPOLZWFYMWNKH-CMKMFDCUSA-N | PubChem API |
| InChIKey (flat) | LLPOLZWFYMWNKH-UHFFFAOYSA-N | ChemIDplus [web-retrieved] |
| SMILES | COc1ccc2c3c1OC1C(=O)CCC4C(C2)N(C)CCC314 | ChemIDplus/PubChem [web-retrieved] |

### Discrepancies with Seed Data
The brief listed empty fields for SMILES, molecular formula, molecular weight, and InChIKey. All four have now been verified via PubChem CID 5284569. The IUPAC name in the seed data matches the PubChem entry exactly. The InChIKey suffix in PubChem (CMKMFDCUSA-N) reflects the defined stereochemistry of the (4R,4aR,7aR,12bS) configuration, consistent with the naturally occurring enantiomer.

### Stereochemistry
Hydrocodone is a semi-synthetic opioid derived from codeine or thebaine. The active form is the (4R,4aR,7aR,12bS) enantiomer, which is the only commercially used configuration. The compound belongs to the morphinan chemical class and shares the characteristic five-ring structure of the morphine alkaloids. The methoxy group at C-3 (position 9 in the IUPAC numbering) distinguishes it from hydromorphone; O-demethylation by CYP2D6 yields the considerably more potent hydromorphone metabolite [Ref 7].

---

## Pharmacology

### Receptor Binding

Hydrocodone is a μ-opioid receptor (MOR) agonist with moderate receptor affinity. Chen et al. (1991 [Ref 7]) established a MOR Ki of **19.8 nM** using rat brain homogenates with ³H-DAMGO as radioligand. In a more recent systematic assessment using recombinant human MOR, Volpe et al. (2011 [Ref 6]) placed hydrocodone in the **Ki = 1–100 nM range**, confirming moderate affinity, ranking it alongside oxycodone, methadone, and fentanyl rather than the higher-affinity opioids (hydromorphone, buprenorphine, sufentanil; Ki < 1 nM) or the lower-affinity drugs (codeine, tramadol; Ki > 100 nM).

A critical pharmacological distinction: hydrocodone's primary active metabolite, hydromorphone, has a MOR Ki of approximately **0.6 nM** — approximately 33-fold greater affinity than hydrocodone itself (Chen et al. 1991 [Ref 7]). Evidence from CYP2D6 pharmacogenomics studies strongly suggests that a meaningful portion of hydrocodone's in vivo analgesic effect is mediated via hydromorphone. Hosseinnejad et al. (2019 [Ref 5]) found in a postcesarean cohort that **plasma hydromorphone, not plasma hydrocodone, was predictive of pain relief**, directly supporting this hypothesis.

**FLAG for generation agent:** Published Ki data at κ-opioid receptor (KOR) and δ-opioid receptor (DOR) for hydrocodone specifically could not be confirmed from literature searches. The brief classifies hydrocodone as both a MOR and KOR agonist; the KOR activity at clinically relevant concentrations is not supported by the primary binding literature reviewed. MOR agonism is established; KOR involvement requires caution or removal from the pharmacological class description pending additional evidence.

### Mechanism of Action
Hydrocodone acts as a full MOR agonist in the central and peripheral nervous system. Activation of MOR inhibits adenylyl cyclase via Gi/Go proteins, reducing cAMP, and modulates ion channels (increased K+ conductance, decreased Ca²+ conductance), ultimately reducing nociceptive signal transmission. Additional effects include suppression of the cough reflex via brainstem MOR activation, decreased gastrointestinal motility through peripheral MOR and enteric nervous system activation, and euphorigenic effects via mesolimbic dopamine pathway modulation.

### Pharmacokinetics

**Metabolic Pathway (well-characterized):**

Hydrocodone undergoes extensive hepatic first-pass metabolism via two primary CYP-mediated pathways (Hutchinson et al. 2004 [Ref 1]; Kapil et al. 2015 [Ref 2]; Barakat et al. 2014 [Ref 3]):

- **CYP3A4 (N-demethylation) → norhydrocodone**: Major pathway; norhydrocodone is considered pharmacologically inactive or weakly active. Mean urinary norhydrocodone mole fraction: approximately **49%** of total (Barakat et al. 2014 [Ref 3])
- **CYP2D6 (O-demethylation) → hydromorphone**: Minor pathway by mass, but pharmacologically significant due to hydromorphone's ~33x higher MOR affinity. Mean urinary hydromorphone mole fraction: approximately **12%** of total [Ref 3]
- Parent hydrocodone accounts for approximately **39%** of urinary drug+metabolites [Ref 3]

Secondary metabolites include dihydrocodeine and dihydromorphine in minor amounts.

**CYP2D6 Pharmacogenomics:**
- CYP2D6 poor metabolizers: substantially reduced hydromorphone formation → reduced analgesia; increased risk of inadequate pain control (Cavallari et al. 2026 [Ref 13]; Nahid et al. 2025 [Ref 14])
- Kapil et al. (2015 [Ref 2]) confirmed with paroxetine co-administration: CYP2D6 inhibition reduced hydromorphone AUC from 3.8 to 0.64 ng·h/mL (83% reduction) while leaving hydrocodone exposure unchanged — demonstrating that CYP2D6 inhibitors alter the hydromorphone:hydrocodone ratio without affecting hydrocodone systemic exposure
- CYP3A4 and CYP3A5 genotype does not significantly predict pain relief from hydrocodone (Hosseinnejad et al. 2019 [Ref 5])

**Extended-Release Pharmacokinetic Parameters** (from Kapil et al. 2015 [Ref 2]):
- **Tmax (ER)**: median 18 hours
- **t½**: 8.4–8.5 hours
- **Cmax** (20 mg ER): 15.9–16.8 ng/mL
- **AUC0-t** (20 mg ER): 325–343 ng·h/mL

**Immediate-Release Pharmacokinetic Parameters:**
Specific published IR single-dose PK studies were not identified through PubMed searches. Based on pharmacokinetic principles for IR oral opioids, Tmax is typically 1–2 hours, substantially shorter than the ER formulation. The biphasic IR/ER combination product (MNK-155) has been characterized (Devarakonda et al. 2015 [Ref 17]). FLAG: IR hydrocodone-specific Tmax, bioavailability, and Cmax data not confirmed from primary PK studies in this research run.

**Food Interaction (ER formulation):**
Farr et al. (2015 [Ref 16]) demonstrated HC-ER relative bioavailability was 101.74% in fed vs. fasted conditions — no clinically meaningful food effect. ER hydrocodone can be taken without regard to meals.

**Alcohol Interaction (ER formulation):**
Farr et al. (2015 [Ref 16]) specifically studied alcohol co-administration with naltrexone-blocked subjects:
- 20% alcohol: no clinically meaningful increase in AUC or Cmax
- 40% alcohol: AUC increased by 20% (832 → 1,008 ng·h/mL); **Cmax increased by ~135%** (46.3 → 109 ng/mL); Tmax shortened from 6.16 to 2.43 hours
- Adverse events occurred in 10% (0% alcohol), 24.1% (20% alcohol), and **66.7%** (40% alcohol) of subjects
- No classical "dose-dumping" (rapid complete drug release) was observed, but the Cmax increase is clinically significant

**Equianalgesic Dose:**
1 mg oral hydrocodone = 1 morphine milligram equivalent (MME), establishing a 1:1 equianalgesic ratio with oral morphine [Ref 31; CDC 2022 guideline Ref 9].

---

## History

### Synthesis and Early Development
Hydrocodone was first synthesized in **Germany in 1920** by **Carl Mannich and Helene Löwenheim**, while investigating reactions that would later be named the Mannich reaction [Ref 18]. It is a semi-synthetic opioid, produced by partial synthesis from codeine (via reduction of the 6-keto group and hydrogenation of the 7,8 double bond from codeine's 6-hydroxy precursor) or occasionally from thebaine. The compound was **patented in 1923** [Ref 18].

### Clinical Introduction (USA)
Hydrocodone received **FDA approval on March 23, 1943** [Ref 18], primarily for use as an antitussive (cough suppressant) and for pain management. For most of its US history it was marketed in combination with acetaminophen (Vicodin, Norco), ibuprofen, or other agents for moderate-to-severe pain. The FDA approved the first single-entity extended-release hydrocodone formulation, Zohydro ER (Zogenix), in October 2013; additional single-entity ER formulations followed (Hysingla ER, Purdue).

### Regulatory History
By 2011, hydrocodone combination products (HCPs) had become the **most prescribed drug class in the United States**, with 136.7 million prescriptions (Manchikanti 2012 [Ref 12]). Under the original Controlled Substances Act framework, hydrocodone itself was Schedule II, but HCPs were classified as **Schedule III** — a classification that created what critics termed the "Vicodin loophole," allowing less-restricted prescribing than single-entity Schedule II opioids.

In response to escalating misuse, overdose deaths, and regulatory pressure, the DEA published a Notice of Proposed Rulemaking in February 2014. The **final rule became effective October 6, 2014**, rescheduling all HCPs from Schedule III to Schedule II [Ref 19]. This imposed the strictest federal prescribing controls: no refills permitted, written or electronic prescriptions required, 30-day supply limits in most states.

Rescheduling consequences: Fleming et al. (2019 [Ref 27]) found 78.8% of surveyed physicians modified their prescribing after rescheduling; Shen et al. (2025 [Ref 20]) documented HCP use declining from 55% to 40% in older breast cancer patients, with compensatory shift to other opioids. Yan et al. (2023 [Ref 21]) documented significant reduction in dental hydrocodone prescribing. Pergolizzi et al. (2017 [Ref 22]) noted the US accounted for ~99% of global hydrocodone consumption.

---

## Subjective Effects

### Published Descriptions
Hydrocodone produces effects typical of full MOR agonists. Direct controlled studies of subjective effects in recreational or non-medical contexts are sparse given ethical constraints, but the clinical literature, forensic toxicology, and pharmacological class profile establish the following effect domains:

**Primary therapeutic/subjective effects (well-documented in clinical and pharmacological literature):**

1. **Pain suppression** — primary therapeutic indication; mediated by central and peripheral MOR activation, with evidence that hydromorphone metabolite contributes meaningfully to analgesic effect [Ref 5]
2. **Sedation** — dose-dependent CNS depression; impairs psychomotor function; standard clinical warning in all published prescribing guidelines [Refs 8, 9]
3. **Euphoria (cognitive and tactile)** — characteristic opioid "rush" or warm glow, particularly at supraanalgesic doses; drives recreational use and dependency liability [Ref 10, Ref 12]
4. **Anxiety suppression** — general CNS depression reduces anxiety and rumination
5. **Constipation** — peripheral MOR activation in GI tract reduces motility; dose-dependent; very common in clinical practice [Refs 10, 11]
6. **Nausea** — central trigger zone (CTZ) activation; common especially with first doses or dose escalation [Refs 10, 11]
7. **Pupil constriction (miosis)** — Edinger-Westphal nucleus activation; diagnostic sign of opioid intoxication [Ref 25]
8. **Respiratory depression** — dose-dependent suppression of respiratory drive; primary mechanism of lethal overdose [Ref 25]
9. **Spontaneous body sensations** — the characteristic warm, itching, or flushing sensation of opioid administration, related to histamine release and MOR activation
10. **Appetite suppression** — documented in clinical opioid literature [Ref 10]
11. **Sexual arousal suppression** — opioid-induced hypogonadism; documented in chronic opioid users [Ref 10]

**Duration data from seed (oral IR):**
- Onset: 10–60 minutes
- Total duration: 4–8 hours
These values are pharmacologically consistent with IR oral opioid kinetics and cross-referenced against CDC prescribing guidance [Refs 8, 9]. **FLAG**: Specific controlled study of IR hydrocodone onset/duration not confirmed from primary pharmacokinetic papers in this research; values derived from clinical descriptions and class pharmacology.

---

## Safety & Toxicity

### Overdose and Fatality
The primary mechanism of lethal overdose is **progressive respiratory depression → apnea → hypoxic death**. Dolinak (2017 [Ref 25]) documents autopsy findings: pulmonary edema and congestion, frothy watery fluid in airways, consistent across opioid-related deaths. Pre-existing cardiorespiratory disease, obesity, or CNS depression from co-ingested substances dramatically lower the lethal threshold.

Harris et al. (JAMA 2026 [Ref 26]) reports opioid use disorder caused 53,774 US deaths in 2024 and affected 3.7% of adults — context for the magnitude of hydrocodone's class risk.

Paulozzi et al. (2006 [Ref 36]) established the causal link between opioid prescribing increases (including hydrocodone) and mortality: opioid analgesic poisoning exceeded heroin and cocaine deaths combined by 2002. Manchikanti (2012 [Ref 12]) documented that opioids became responsible for more deaths than suicide and motor vehicle crashes.

**Dose-Dependent Risk:**
The seed data characterizes acute and chronic toxicity as "high" and notes potential fatality at heavy dosages. This is consistent with the published literature. No specific LD50 studies in humans exist (ethical constraints). In naïve individuals, doses well within the "heavy" range (40+ mg) may be lethal, particularly with CNS depressant co-ingestion. Opioid-tolerant individuals may require much higher doses to achieve the same respiratory depression.

**Acetaminophen Hepatotoxicity (Combination Products):**
The most-used formulations pair hydrocodone with acetaminophen. Yoon et al. (2016 [Ref — see OpenAlex results]) document that acetaminophen accounts for >50% of US overdose-related acute liver failure. The FDA mandated in 2014 that combination products contain no more than 325 mg acetaminophen per dosage unit to limit hepatotoxicity risk. This is a critical safety distinction: **hepatotoxicity risk in hydrocodone overdose typically comes from the acetaminophen component, not hydrocodone itself**.

### Naloxone Reversal
Naloxone is a competitive MOR antagonist that effectively reverses opioid-induced respiratory depression and can be lifesaving in hydrocodone overdose [Ref 26]. Multiple doses may be required given hydrocodone's duration of action (4–8 hours), as naloxone's duration (30–90 min IV) may be shorter.

---

## Harm Reduction

### Published Risk Reduction Strategies

1. **Avoid CNS depressant combinations**: Benzodiazepines, alcohol, GHB/GBL, muscle relaxants, and other sedating substances potentiate respiratory depression and dramatically increase fatality risk [Refs 16, 24, 30, 35]
2. **CYP2D6 awareness**: Poor metabolizers may experience inadequate analgesia and be at risk of escalating doses; ultra-rapid metabolizers may experience stronger effects at standard doses [Refs 1, 2, 13]
3. **Never combine with high-proof alcohol**: 40% ethanol significantly increases hydrocodone Cmax and accelerates Tmax even for the ER formulation [Ref 16]
4. **Naloxone access**: Take-home naloxone programs are effective at reducing opioid overdose mortality [Ref 26]
5. **Avoid in liver impairment**: Altered CYP3A4 activity changes norhydrocodone:hydromorphone ratio and increases unpredictability
6. **Never share prescriptions**: Opioid combination products contain acetaminophen; untrained users may exceed safe acetaminophen limits

### Contraindications (from literature and class pharmacology)
- Severe respiratory depression or acute asthma (package insert level)
- Concurrent MAOI use (serotonergic risk via mechanisms not fully characterized for hydrocodone)
- Known hypersensitivity to hydrocodone
- Pregnancy: neonatal opioid withdrawal syndrome (NOWS) documented; data gaps noted for maternal pharmacokinetics [Ref 15]
- Head injury/elevated ICP: opioids increase CSF pressure and confound neurological assessment

---

## Tolerance & Dependence

### Tolerance Development
Opioid tolerance develops through μ-opioid receptor desensitization (GRK phosphorylation → β-arrestin recruitment → receptor internalization) and downregulation. Cellular studies in Neuro2A cells expressing cloned MOR confirm time- and concentration-dependent desensitization with complete cross-tolerance demonstrated across MOR agonists. Tolerance typically manifests as reduced analgesic effect requiring dose escalation. The seed data characterizes tolerance buildup as "with prolonged use," consistent with the published literature. Cross-tolerance occurs with all MOR agonists.

**Tolerance Reset Timeline (seed data, consistent with class pharmacology):**
- Half-life of tolerance: 5 days
- Full reset: ~1.5 weeks
These values are broadly consistent with clinical observations of opioid tapering but are not confirmed by specific hydrocodone tolerance studies; FLAG noted below.

### Dependence and Withdrawal
Physical and psychological dependence develop with regular use. The opioid withdrawal syndrome is characterized by anxiety, insomnia, muscle pain, GI distress (nausea, vomiting, diarrhea), sweating, piloerection, yawning, and tachycardia, reflecting rebound sympathetic activation when MOR agonism is withdrawn.

The seed data rates physical and psychological dependence both as "moderate" — appropriate for a Schedule II full MOR agonist. Hydrocodone produces milder physical dependence than high-potency opioids (heroin, hydromorphone) but more than partial agonists (buprenorphine) at equivalent analgesic doses.

Treatment options: buprenorphine-naloxone (partial agonist substitution), methadone (full agonist substitution), naltrexone (antagonist relapse prevention), all with evidence base reviewed by Harris et al. (JAMA 2026 [Ref 26]).

---

## Interactions

### Interactions Listed in Brief — Verified Against Literature

**Alcohol — LETHAL**
*Confirmed.* Pharmacodynamic mechanism (additive CNS and respiratory depression) plus pharmacokinetic mechanism (40% ethanol increases Cmax ~135% and shortens Tmax) documented by Farr et al. (2015 [Ref 16]). Even lower alcohol concentrations (20%) increase adverse event rates. Jann et al. (2014 [Ref 24]) confirm alcohol+opioid combinations as a major contributor to fatal overdose. Evidence quality: high.

**GBL/GHB — LETHAL**
*Confirmed by mechanism.* GHB acts as a GABA-B receptor agonist, producing CNS depression via GABAergic and endogenous GHB receptor pathways. Combined with opioid MOR-mediated CNS depression, the result is additive or synergistic respiratory depression [Ref 30]. Critically, **naloxone does not reverse GHB-induced respiratory depression** — only opioid-mediated effects are reversed. No published hydrocodone+GHB-specific case series identified; interaction is supported by class pharmacology and GHB toxicology literature [Ref 30].

**Tramadol — LETHAL**
*Supported by mechanism; interaction is complex.* Tramadol is a dual-mechanism drug: MOR agonism (via active M1 metabolite) plus serotonin/norepinephrine reuptake inhibition. Combined with hydrocodone (full MOR agonist), the result is additive opioid-mediated respiratory depression. Additionally, tramadol lowers seizure threshold, and the combination increases seizure risk. Lagard et al. (2016 [Ref — from tramadol search]) demonstrate that benzodiazepine+tramadol paradoxically worsens respiratory depression. Evidence quality: moderate (animal data; class pharmacology reasoning; limited direct hydrocodone+tramadol human data).

**Ketamine — LETHAL (per brief)**
*Partially supported.* Ketamine is a dissociative NMDA antagonist with dose-dependent CNS depressant effects at subanesthetic doses. Co-administration with opioids is standard in procedural sedation when carefully monitored, but combined CNS depression, cardiovascular suppression, and respiratory effects at recreational doses can be dangerous. No hydrocodone+ketamine-specific lethality data identified; interaction is supported by class-level CNS depression pharmacology. Evidence quality: weak for the "lethal" classification specifically.

**Nitrous Oxide — UNKNOWN (per brief)**
Literature on hydrocodone+nitrous oxide interaction is essentially absent. Nitrous oxide has weak MOR agonist activity and can enhance opioid analgesia. Combination increases CNS depression and may enhance respiratory impairment. Categorized as unknown is appropriate; evidence quality: insufficient.

**PCP — UNKNOWN (per brief)**
No hydrocodone+PCP interaction data identified. Both are CNS-active; combined CNS depression is plausible. Evidence quality: insufficient.

### Additional Interactions from Literature

**Benzodiazepines (not listed in brief but safety-critical):**
Fields et al. (2015 [Ref 35]) found alprazolam+diazepam co-ingestion significantly decreased hydrocodone blood concentrations in postmortem cases (likely via CYP3A4 competition) while deaths still occurred — indicating synergistic CNS toxicity occurring at lower drug concentrations. Jann et al. (2014 [Ref 24]) confirm 5-fold increase in benzodiazepine-related deaths from 1999–2009, largely driven by opioid co-ingestion. **FLAG:** Benzodiazepines are absent from the brief's interactions list but are a primary cause of opioid overdose death and should be added as at minimum a "dangerous" or "lethal" interaction.

**CYP2D6 Inhibitors (paroxetine, fluoxetine, bupropion):**
Substantially reduce hydromorphone formation, potentially reducing analgesia without reducing sedation or respiratory depression (since hydrocodone itself still contributes to both). Clinical significance: analgesia-sedation dissociation in poor metabolizers and with CYP2D6 inhibitors [Refs 2, 5].

**CYP3A4 Inhibitors (azole antifungals, clarithromycin, grapefruit):**
Would be expected to reduce norhydrocodone formation, shifting balance toward more hydromorphone production and potentially increasing respiratory depression risk. No direct hydrocodone+CYP3A4 inhibitor clinical study identified in this research.

---

## Legal Status

| Jurisdiction | Schedule/Classification | Notes |
|---|---|---|
| United States | Schedule II (DEA) | Effective October 6, 2014; HCPs previously Schedule III (1970–2014) [Ref 19] |
| United Kingdom | Class A, Controlled Drug | Misuse of Drugs Act 1971 [web-retrieved] |
| Canada | Controlled substance (narcotic) | Available as Hycodan brand [Ref 18] |
| Australia | Schedule 8 (inferred) | Strong opioids are typically Schedule 8 under SUSMP; not confirmed from primary regulatory source |
| EU | Controlled narcotic | Not commercially available in most EU states |

**FLAG:** Australia scheduling confirmed by inference only. A primary source check with the TGA/SUSMP database is recommended before publication. Canadian scheduling classification (CDSA schedule number) was not confirmed from primary source.

---

## Clinical Trials

### Relevant Completed Trials

**NCT00402792 (Phase 3, Completed, Abbott)**
- Title: A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy
- Condition: Acute Pain
- Sponsor: Abbott
- Status: Completed [Ref 32]

**NCT01333722 (Phase 2, Completed, Abbott/AbbVie)**
- Title: Acute Pain Study Following Bunionectomy
- Condition: Acute Pain
- Sponsor: AbbVie (prior Abbott)
- Status: Completed [Ref 33]

### Recent Comparative Trials
Suzetrigine (VX-548) Phase 3 trials (Bertoch et al. 2025 [PMID 40117446]) compared the novel NaV1.8 inhibitor against hydrocodone bitartrate 5 mg/acetaminophen 300 mg as an active comparator in bunionectomy and abdominoplasty pain. VX-548 showed non-inferior efficacy to hydrocodone/APAP in these trials — establishing hydrocodone/APAP as the current clinical standard against which novel analgesics are benchmarked.

Farrar et al. (2022 [PMID 34261978]) conducted a harmonization analysis of FDA patient-level data from abuse-deterrent oxycodone and hydrocodone studies: only ~44.5% of 3,192 chronic non-cancer pain patients maintained pain level and opioid dose stability over 12 months.

---

## Community Feedback Analysis

**No community feedback submitted.** Part A2 of the brief is empty. Standard research directives applied.

---

## Gaps & Flags

### Data Gaps

1. **Immediate-release (IR) PK parameters**: Tmax, bioavailability, Cmax for standard IR hydrocodone tablets (e.g., 5 mg, 10 mg) were not found in primary PK studies in this research run. IR PK data is referenced in prescribing labels but primary clinical pharmacokinetic study data specific to IR formulations was not retrieved. The brief's onset data (10–60 min) is consistent with expected IR opioid Tmax but not confirmed from a specific primary source.

2. **Oral bioavailability percentage**: A specific bioavailability figure (%) for oral hydrocodone was not found in the retrieved literature. PK studies provide AUC and Cmax data but absolute bioavailability vs. IV reference is not established in the papers reviewed.

3. **KOR binding affinity**: The brief classifies hydrocodone as a κ-opioid receptor agonist, but no published Ki or EC50 data at KOR were found in primary pharmacological literature. The classification may derive from structural analogy with morphinan opioids. **FLAG for editorial review**: KOR agonism is not supported by primary pharmacological literature reviewed here.

4. **Physical properties**: Melting point, aqueous solubility, and LogP for hydrocodone were not retrieved. These are likely in Chemeo/NIST databases but were not confirmed through API tools in this research.

5. **LD50 data**: No published human LD50 or TI (therapeutic index) data for hydrocodone. Rat LD50 data likely exists in pharmaceutical literature but was not retrieved.

6. **Protein binding**: Hydrocodone protein binding data (expected ~35–45% for morphinan opioids) was not retrieved from primary sources.

### Safety-Critical Flags

7. **Benzodiazepine interaction missing from seed**: The brief's interaction list does not include benzodiazepines despite strong published evidence (Fields 2015 [Ref 35]; Jann 2014 [Ref 24]) that benzo+opioid combinations substantially increase overdose mortality. **Recommend adding benzodiazepines as a "lethal" or at minimum "dangerous" interaction**. This is a significant safety gap.

8. **Ketamine "lethal" classification**: The brief rates the ketamine interaction as lethal. Literature support for this specific combination is weak — the interaction is theoretically plausible via additive CNS depression but no direct hydrocodone+ketamine lethality data was found. May need downgrade to "dangerous" pending more specific evidence.

9. **Tolerance reset timeline not confirmed from primary sources**: The seed data tolerance half-life (5 days) and full reset (1.5 weeks) are broadly plausible for a short-acting opioid but were not confirmed against hydrocodone-specific tolerance studies.

10. **Australia scheduling**: Classified as Schedule 8 by inference only. Requires primary regulatory source confirmation.

11. **KOR agonist classification**: Not supported by primary binding literature reviewed. Recommend flagging this for editorial review before article generation uses it.

12. **Dose data note**: The brief's dose ranges (Threshold 3 mg; Light 5–10 mg; Common 10–25 mg; Strong 25–40 mg; Heavy 40+ mg) are for oral IR hydrocodone and appear pharmacologically reasonable. These are higher than typical starting analgesic doses for opioid-naive patients (5 mg), which likely reflects the recreational/psychoactive context. No specific primary study validating these exact recreational dose thresholds was identified; values are consistent with class pharmacology and appear to reflect community-derived data that is structurally plausible.

### Contradictions

13. **"Emerging" characterization in seed**: The brief categorizes hydrocodone as "emerging," which conflicts with its status as one of the most-studied, most-prescribed, and most-regulated opioids in history. This is almost certainly a database error. Hydrocodone is extremely well-characterized in the medical literature.

14. **KOR classification vs. literature**: Brief lists "Kappa-opioid receptor agonist" as a pharmacological class. This is not supported by the primary binding affinity literature reviewed and should be reviewed by an editor.